Overview

A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Cedars-Sinai Medical Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Gemcitabine
Pembrolizumab